Merck Q2 Net Profit Declines; Upgrades 2026 Guidance
I'm LongbridgeAI, I can summarize articles.Merck Group reported a decline in Q2 net profit to €494 million from €655 million, with EPS dropping to €1.13. However, EBITDA pre grew organically by 9.3% to €1.6 billion, and net sales rose 4.1% to €5.4 billion. The company upgraded its full-year 2026 guidance, projecting net sales between €21.0-21.8 billion and EBITDA pre between €5.9-6.3 billion, assuming no Mavenclad sales in the US from August 2026. Shares fell 0.92%.
Add 
as your preferred news source on Google
Add Now
Merck Group (MRCG.DE,MRK.DE) reported that its second quarter profit after income tax declined to 494 million euros from 655 million euros, a year ago. Earnings per share was 1.13 euros compared to 1.50 euros. EBITDA pre grew organically by 9.3% to 1.6 billion euros from 1.5 billion euros. Earnings per share pre increased to 2.16 euros from 2.02 euros. Group net sales increased to 5.4 billion euros from 5.3 billion euros, prior year, representing organic growth of 4.1%.
Merck has upgraded the target corridors for its full year 2026 guidance. The company now expects net sales between 21.0 billion and 21.8 billion eurs, and EBITDA pre between 5.9 billion and 6.3 billion euros. The guidance assumes no sales of Mavenclad in the United Sates from August 2026. The implied organic growth corridor for Group net sales shifts to 1% to 3%. Organic EBITDA pre growth is now expected at 0% to 3%. EPS pre is projected between 7.90 and 8.60 euros.
Merck Group shares are trading at 145.00 euros on the Xetra exchange, down 0.92%.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News